XIST and neoplasm: To further explore whether targeting the NAT10/XIST/YAP1 axis augments the antitumor effect of immune checkpoint inhibitors (ICIs), we administered Remodelin, Verteporfin, and an anti-PD-1 monoclonal antibody to tumor-bearing mice.